Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Novel immune checkpoint blockade with ipilimumab, an antibody blocking the cytotoxic T-lymphocyte antigen 4 (CTLA4), is revolutionizing cancer therapy. However, ipilimumab induces symptomatic, sometimes severe, endocrine immune-related adverse events (irAEs) that are inconsistently recognized and reported. The objective of this review was to comprehensively characterize the incidence, presentation, and management of endocrinopathies following ipilimumab therapy in a single center that is highly specialized in immune checkpoint blockade. We carried out a retrospective analysis of endocrine irAEs in melanoma patients receiving ipilimumab therapy in clinical trials between 2007 and 2013. A total of 256 patients were included in this analysis. We reviewed pituitary-, thyroid-, and adrenal-related hormone test results, as well as radiographic studies and the clinical histories of patients, to identify and characterize cases of hypophysitis, hypothyroidism, thyroiditis, and adrenal dysfunction. Following ipilimumab therapy, the overall incidence of hypophysitis was 8% and that of hypothyroidism/thyroiditis 6%. Primary adrenal dysfunction was rare. Therapy with a combination of ipilimumab and nivolumab, an anti-programmed cell death 1 (PDCD1, also called PD1) receptor antibody, was associated with a 22% incidence of either thyroiditis or hypothyroidism and a 9% incidence of hypophysitis. Symptomatic relief, in particular, for hypophysitis, was achieved in all patients with hormone replacement, although endogenous hormone secretion rarely recovered. In summary, we observed that CTLA4 blockade alone, and in particular in combination with PD1 blockade, is associated with an increased risk of symptomatic, sometimes severe, hypophysitis as well as thyroid dysfunction. Prompt initiation with hormone replacement reverses symptoms. Evaluation and reporting of endocrine irAEs in clinical trials should be done using standardized diagnostic criteria and terminology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“novel biological drugs inducing hypophysitis such as ipilimumab or other check-point inhibitors (63).”
From The diagnosis and management of central hypothyroidism in 2018 (2019) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the literature, female gender is described as being a risk factor for ICPi-induced TD, although this is less pronounced than in spontaneous forms [7,46,47] and it is not described in all studies [11,48].”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [46]
Experimental — accuracy not yet measuredIn the citing paper
“the rexinoids (e.g. bexarotene), directly repressing TSHβ expression”
From The diagnosis and management of central hypothyroidism in 2018 (2019) · cites this paper as [63]
In the citing paper
“mitotane, which decreases viability of thyrotrope cells”
From The diagnosis and management of central hypothyroidism in 2018 (2019) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 6×
“The higher overall incidence of hypophysitis in the studies (8%) reviewed compared with that in most of the published trials probably reflects our welldefined clinical, biochemical, and radiographic criteria for identifying cases, which is highly inconsistent and ambiguous in published clinical trials (Hodi et al. 201…”
BackgroundResultInfluentialSelf-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“Nivolumab, a second antibody-derived immune regulator, blocks the activation of the anti-programmed cell death 1 (PDCD1, also called PD1) receptor (Topalian et al. 2012).”
BackgroundAssociation of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175 · cited 2×
“…pituitary hormone secretion. http://erc.endocrinology-journals.org q 2014 Society for Endocrinology DOI: 10.1530/ERC-13-0499 Printed in Great Britain There is a clear association betweenCTLA4 and sporadic, autoimmune thyroid disease in humans and mice (Tomer et al. 2001, Ueda et al. 2003).”
BackgroundInfluentialCTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940 · cited 1×
“The engagement of CTLA4 by its ligands in the B7 co-stimulatory family suppresses T-cell proliferation, helping restore tissue homeostasis (Egen et al. 2002, Pentcheva-Hoang et al. 2004).”
BackgroundCaturegli, P., Newschaffer, C., Olivi, A., Pomper, M. G., Burger, P. C., & Rose, N. R. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0011 · Cited by 588
Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
Lipson, E. J., & Drake, C. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1595 · Cited by 570
B7-1 and B7-2 Selectively Recruit CTLA-4 and CD28 to the Immunological Synapse
Pentcheva-Hoang, T., Egen, J. G., Wojnoonski, K., & Allison, J. P. (2004) · Immunity · doi:10.1016/j.immuni.2004.06.017 · Cited by 436
Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
Corsello, S. M., Barnabei, A., Marchetti, P., De Vecchis, L., Salvatori, R., & Torino, F. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4075 · Cited by 403
Blansfield, J. A., Beck, K. E., Tran, K., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Topalian, S. L., Haworth, L. R., Levy, C., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000178913.41256.06 · Cited by 355
Dillard, T., Yedinak, C. G., Alumkal, J., & Fleseriu, M. (2010) · Pituitary · doi:10.1007/s11102-009-0193-z · Cited by 300
Research works printed but not linked: 1
- 2005, 28, 593
Cited by
Items 201–300 of 460
Anderson, M., Kurra, V., Bradley, W. R., Kilcoyne, A., Mojtahed, A., & Lee, S. I. (2020) · British Journal of Radiology · doi:10.1259/bjr.20200663 · Cited by 25
Garon-Czmil, J., Petitpain, N., Rouby, F., Sassier, M., Babai, S., Yelehe‐Okouma, M., Weryha, G., Klein, M., & Gillet, P. (2018) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12423 · Cited by 25
Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer
Yang, J., Chen, J., Wei, J., Liu, X., & Cho, W. C. S. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1214265 · Cited by 25
Patient-Centered Diabetes Care of Cancer Patients
Kotwal, A., Cheung, Y.-M. M., Cromwell, G. E., Drincic, A., Leblebjian, H., Quandt, Z., Rushakoff, R. J., & McDonnell, M. E. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01435-y · Cited by 24
Lee, S., Lee, S., Cho, H., Min, K., Hong, J. H., Song, J. Y., Lee, J. K., & Lee, N. W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24020974 · Cited by 23
Anticancer Medications and Sodium Dysmetabolism
Krishnamurthy, A., Bhattacharya, S., Lathia, T. B., Kantroo, V., Kalra, S., & Dutta, D. (2020) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2020.16.2.122 · Cited by 23
Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists
Callahan, M. K., & Wolchok, J. D. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.008 · Cited by 23
Self-citationOptimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?
Music, M., Prassas, I., & Diamandis, E. P. (2018) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2018.1499706 · Cited by 23
The safety of anti PD-1 therapeutics for the treatment of melanoma
Ramelyte, E., Hogan, S. A., & Dummer, R. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1248402 · Cited by 23
Antoniou, S., Bazazo, G., Röckl, L., Papadakis, M., & Berg, C. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00854-y · Cited by 23
Nivolumab, a new immunomodulatory drug, a new adverse effect; adrenal crisis
Akarca, F. K., Can, O., Yalcinli, S., & Altunci, Y. A. (2017) · Turkish Journal of Emergency Medicine · doi:10.1016/j.tjem.2017.05.007 · Cited by 22
Endocrinopathies Associated With Immune Checkpoint Inhibitor Use
Kotwal, A., Kennedy, R., Kikani, N. J., Thosani, S., Goldner, W. S., & Shariff, A. I. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.03.023 · Cited by 22
Immunotherapy-Related Hypophysitis: A Narrative Review
Stasi, V. D., Sala, D. L., Cozzi, R. C., Scavuzzo, F., Geronimo, V. D., Poggi, M., Vitale, M., & Tortora, A. (2025) · Cancers · doi:10.3390/cancers17030436 · Cited by 22
Immune checkpoint inhibitors as a threat to reproductive function: A systematic review
Tuerxun, H., Zhao, Y., Li, Y., Liu, X., Wen, S., Cao, J., Cao, J., & Zhao, Y. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104064 · Cited by 22
Deligiorgi, M. V., Sagredou, S., Vakkas, L., & Trafalis, D. T. (2021) · Cancers · doi:10.3390/cancers13215277 · Cited by 22
Endocrine dysfunction following immune checkpoint inhibitor therapy
Konda, B., Nabhan, F. A., & Shah, M. H. (2017) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000357 · Cited by 21
Alrifai, T., Ali, F. S., Saleem, S., Ruiz, D., Rifai, D., Younas, S., & Qureshi, F. M. (2019) · Case Reports in Oncological Medicine · doi:10.1155/2019/8781347 · Cited by 21
Sharma, R. B., Dalmazi, G. D., & Caturegli, P. (2016) · Thyroid · doi:10.1089/thy.2016.0092 · Cited by 21
Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC
Zhou, N., Velez, M. A., Bachrach, B., Gukasyan, J., Fares, C. M., Cummings, A. L., Lind-Lebuffe, J. P., Akingbemi, W. O., Li, D., Brodrick, P. M., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.08.009 · Cited by 20
Hypophysitis from immune checkpoint inhibitors: challenges in diagnosis and management
Kotwal, A. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000652 · Cited by 20
van der Leij, S., Suijkerbuijk, K. P. M., van den Broek, M. F. M., Valk, G. D., Dankbaar, J. W., & van Santen, H. M. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1400841 · Cited by 20
Nivolumab-induced thyroid dysfunction in patients with lung cancer
Ramos-Levi, A. M., Rogado, J., Sánchez-Torres, J. M., Colomer, R., & Marazuela, M. (2018) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.05.005 · Cited by 20
Perspectives for immunotherapy in endocrine cancer
Latteyer, S., Tiedje, V., Schilling, B., & Führer, D. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0169 · Cited by 20
Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review
Dudzińska, M., Szczyrek, M., Wojas‐Krawczyk, K., Świrska, J., Chmielewska, I., & Zwolak, A. (2020) · Cancers · doi:10.3390/cancers12082314 · Cited by 20
Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors
Cheema, P. K., Iafolla, M. A. J., Abdel-Qadir, H. M., Bellini, A. B., Chatur, N., Chandok, N., Comondore, V. R., Cunningham, M. E., Halperin, I. J., Hu, A. C., et al. (2024) · Current Oncology · doi:10.3390/curroncol31100473 · Cited by 20
George, A. S., Fernandez, C. J., Eapen, D., & Pappachan, J. M. (2021) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2021.17.1.21 · Cited by 19
Sood, A., Cole, D. W., Abdollah, F., Eilender, B., Roumayah, Z., Deebajah, M., Dabaja, A. A., & Alanee, S. R. (2018) · Current Urology Reports · doi:10.1007/s11934-018-0819-7 · Cited by 19
Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH
Siddiqui, M. S., Lai, Z. M., Spain, L. A., Greener, V., Turajlic, S., Larkin, J., & Morganstein, D. L. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01297-3 · Cited by 19
Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma
Alnabulsi, R., Hussain, A., & DeAngelis, D. (2018) · Orbit · doi:10.1080/01676830.2017.1423349 · Cited by 19
Nivolumab causing painless thyroiditis in a patient with adenocarcinoma of the lung
Verma, I., Modi, A., Tripathi, H., & Agrawal, A. (2016) · BMJ Case Reports · doi:10.1136/bcr-2015-213692 · Cited by 18
The management of immune-related adverse events associated with immune checkpoint blockade
Fay, A. P., Moreira, R. B., Filho, P. R. S. N., Albuquerque, C., & Barrios, C. H. (2016) · Expert Review of Quality of Life in Cancer Care · doi:10.1080/23809000.2016.1142827 · Cited by 18
Endocrine immune-related adverse effects of immune-checkpoint inhibitors
Trevisani, V., Iughetti, L., Lucaccioni, L., & Predieri, B. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2256841 · Cited by 18
The crossroads between cancer immunity and autoimmunity antibodies to self antigens
Bei, R. (2017) · Frontiers in bioscience · doi:10.2741/4545 · Cited by 18
Cardiotoxicity of Cancer Therapies
Mondal, P., Jain, D., Aronow, W. S., & Frishman, W. H. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000239 · Cited by 18
Kotwal, A., & Ryder, M. M. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000664 · Cited by 17
Self-citationThe Diagnosis and Management of Endocrine Side Effects of Immune Checkpoint Inhibitors
Mai, K., Faßnacht, M., Führer‐Sakel, D., Honegger, J. B., Weber, M. M., & Kroiß, M. (2021) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2021.0143 · Cited by 17
Autoimmune Polyglandular Syndromes
Sperling, M. A., Angelousi, A. G., & Yau, M. (2021) · MDText.com, Inc. eBooks · Cited by 17
Perspective on potential impact of HIV central nervous system latency on eradication
Chan, P., & Ananworanich, J. (2019) · AIDS · doi:10.1097/qad.0000000000002264 · Cited by 17
Harnessing Immune Checkpoints for Cancer Therapy
Vinay, D. S., & Kwon, B. S. (2018) · Immunotherapy · doi:10.2217/imt-2017-0168 · Cited by 17
Chen, J., Wen, Y., Chu, X., Liu, Y., & Su, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.944342 · Cited by 17
ProTECT—Prediction of T-Cell Epitopes for Cancer Therapy
Rao, A. A., Madejska, A. A., Pfeil, J., Paten, B., Salama, S. R., & Haussler, D. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.483296 · Cited by 17
Ntemou, E., Delgouffe, E., & Goossens, E. (2024) · Cancers · doi:10.3390/cancers16061176 · Cited by 17
Deligiorgi, M. V., Panayiotidis, M. I., & Trafalis, D. T. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105942 · Cited by 17
Yaura, K., Sakurai, K., Niitsuma, S., Sato, R., Takahashi, K., & Arihara, Z. (2021) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.254.253 · Cited by 17
The confused oncologic patient: a rational clinical approach
Nolan, C. P., & DeAngelis, L. M. (2016) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000392 · Cited by 17
Ikesue, H., Kusuda, K., Satsuma, Y., Nishiwaki, F., Miura, R., Masuda, Y., Hirabatake, M., Muroi, N., Fujimoto, D., Morimoto, T., et al. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13207 · Cited by 17
Immune-related endocrine disorders in novel immune checkpoint inhibition therapy
Min, L. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.10.002 · Cited by 16
Expert opinions on adrenal complications in immunotherapy
Haissaguerre, M., Hescot, S., Bertherat, J. Y., & Chabre, O. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.07.002 · Cited by 16
Zatelli, M. C., Faggiano, A., Argentiero, A., Danesi, R., D’Oronzo, S., Fogli, S., Franchina, T., Giorgino, F., Marrano, N., Giuffrida, D., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102734 · Cited by 16
Sasaki, K., Kobayashi, S., Kudo, M., Sugimoto, M., Takahashi, S., Nakamura, Y., Kawazoe, A., Shitara, K., Kinoshita, T., & Gotohda, N. (2021) · Surgical Case Reports · doi:10.1186/s40792-021-01346-w · Cited by 16
Diamanti‐Kandarakis, E., Duntas, L. H., Kanakis, G., Kandaraki, E., Karavitaki, N., Kassi, E. N., Livadas, S., Mastorakos, G. P., Migdalis, I. N., Miras, A. D., et al. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0154 · Cited by 16
Kähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Mößner, R., Ugurel, S., Zimmer, L., Gutzmer, R., & (ADO), F. D. K. „. N. D. A. D. O. (2016) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13047_g · Cited by 16
Yuan, K., Zeng, R., Deng, P., Zhang, A., Liu, H., Wang, N., Tang, Y., Yin, Z., & Liu, H. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s345123 · Cited by 16
Systemic Adverse Events with Biomedicines
Tridente, G. (2014) · Cited by 15
Synergistic effects of radiotherapy and immunotherapy: improving oncological outcomes
Chen, X., Liu, W., Wang, Y., Yue, Z., Wang, J., Liu, Y., Xu, L., & Hu, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1771355 · Cited by 15
Harui, A., McLachlan, S. M., Rapoport, B., Zarembinski, T. I., & Roth, M. D. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02579-8 · Cited by 15
Review of the recent clinical trials for PD-1/PD-L1 based lung cancer immunotherapy
Behrouzieh, S., Sheida, F., & Rezaei, N. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1996230 · Cited by 14
Liu, G., Qiu, Y., Zhang, P., Chen, Z., Chen, S., Huang, W., Wang, B., Yu, X., & Guo, D. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091762 · Cited by 14
Introduction to expert opinion on endocrine complications of new anticancer therapies
Castinetti, F., & Borson‐Chazot, F. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.07.001 · Cited by 14
Mills, T. A., Orloff, M. M., Domingo‐Vidal, M., Cotzia, P., Birbe, R., Draganova‐Tacheva, R., Cantarin, M. P. M., Tuluc, M., & Martinez‐Outschoorn, U. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.006 · Cited by 14
Theiler‐Schwetz, V., Trummer, C., Schmitt, L., Terbuch, A., Obermayer-Pietsch, B. M., Richtig, E., & Pilz, S. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2453829 · Cited by 14
Babalola, B. A., Adebami, G. E., & Akinsuyi, O. (2021) · Global Journal of Cancer Therapy · doi:10.17352/2581-5407.000040 · Cited by 14
Angelousi, A. G., Papalexis, P., Karampela, A., Marra, M., Misthos, D., Ziogas, D. I., & Gogas, H. J. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11709 · Cited by 14
Cutaneous Reactions to Targeted Therapy
Lee, J. J., Kroshinsky, D., & Hoang, M. P. (2017) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000000504 · Cited by 14
Massa, G., Zambelli, L., Zecca, E., Shkodra, M., Tinè, G., & Caraceni, A. T. (2024) · The Oncologist · doi:10.1093/oncolo/oyae024 · Cited by 13
Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces
Deligiorgi, M. V., Liapi, C. A., & Trafalis, D. T. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1869211 · Cited by 13
Endocrine Adverse Events Related with Immune Checkpoint Inhibitors: An Update for Clinicians
Deligiorgi, M. V., Panayiotidis, M. I., & Trafalis, D. T. (2020) · Immunotherapy · doi:10.2217/imt-2019-0132 · Cited by 13
Helderman, N. C., Lucas, M. W., & Blank, C. U. (2023) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2023.100374 · Cited by 13
Florez, N., Kiel, L., Meza, K., Wei, Z., Mazzola, E., Velázquez, A. I., Franco, I. “., Fidler, M. J., Elkins, I., Feldman, J., et al. (2023) · Cancer · doi:10.1002/cncr.35057 · Cited by 13
Top Ten Tips for Palliative Care Clinicians Caring for Cancer Patients Receiving Immunotherapies
Wiesenthal, A. C., Patel, S. P., LeBlanc, T. W., Roeland, E. J., & Kamal, A. H. (2018) · Journal of Palliative Medicine · doi:10.1089/jpm.2018.0107 · Cited by 13
Sidhu, P., Menzies, A. M., Long, G. V., Carlino, M. S., Lorens, S., & Kapoor, R. (2017) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.12653 · Cited by 13
Newman, C., Kgosidialwa, O., Hakami, O. A., Kennedy, C., Grogan, L., & Agha, A. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00693-x · Cited by 13
Ipilimumab‐induced hypophysitis: early Australian experience
Sousa, S. M. C. D., Long, G. V., & Tonks, K. T. T. (2014) · The Medical Journal of Australia · doi:10.5694/mja14.00803 · Cited by 12
Group 3: Strategies for identifying the cause of adrenal insufficiency: diagnostic algorithms
Proust-Lemoine, E., Reynaud, R., Delemer, B., Tabarin, A., & Samara‐Boustani, D. (2017) · Annales d Endocrinologie · doi:10.1016/j.ando.2017.10.006 · Cited by 12
Hou, Y., Wang, D., Hu, J., Tian, R., Wang, W., Su, Q., Li, H., & Wang, Y. (2021) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2021.1890133 · Cited by 12
Emergency Presentations of Immune Checkpoint Inhibitor-Related Endocrinopathies
Knight, T., & Cooksley, T. (2021) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2021.02.020 · Cited by 12
Endocrine dysfunction induced by immune checkpoint inhibitors.
Deligiannis, N. G., Sosa, S., Danilowicz, K., & Rizzo, L. F. L. (2021) · PubMed · Cited by 12
Furubayashi, N., Negishi, T., Uozumi, T., Takamatsu, D., Shiraishi, K., Hirose, D., & Nakamura, M. (2018) · Molecular and Clinical Oncology · doi:10.3892/mco.2018.1781 · Cited by 12
Kotwal, A., Perlman, J. E., Goldner, W. S., Marr, A., & Mammen, J. S. (2023) · JCO Oncology Practice · doi:10.1200/op.23.00023 · Cited by 11
Les dysthyroïdies sous immunothérapie anti-cancéreuse
Anceau, C. C., Abeillon, J., Maillet, D., Borson‐Chazot, F., & Disse, E. (2019) · Bulletin du Cancer · doi:10.1016/j.bulcan.2019.10.005 · Cited by 11
Seery, V. J. (2017) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2017.08.002 · Cited by 11
Toxicities from immunotherapy: From clinical trials to real-world clinical practice
Riveiro‐Barciela, M., Araguás, E. T., Martínez‐Valle, F., Roca-Herrera, M., Zamora, E., Barreira‐Díaz, A., & Muñoz‐Couselo, E. (2020) · Medicina Clínica · doi:10.1016/j.medcli.2020.06.057 · Cited by 11
Early Serum Markers for Immune Checkpoint Inhibitor Induced Hypophysitis in Melanoma Patients
Mitri, F., Machiraju, D., Naoum, C., & Hassel, J. C. (2024) · Cancers · doi:10.3390/cancers16071340 · Cited by 11
Abid, H., Khavandi, M., Siddiqui, N., Panjawatanan, P., & Patel, A. V. (2019) · Cureus · doi:10.7759/cureus.5997 · Cited by 11
Majchel, D., & Korytkowski, M. T. (2015) · Case Reports in Endocrinology · doi:10.1155/2015/570293 · Cited by 10
Endocrine dysfunctions during treatment of immune-checkpoint inhibitors
Inaba, H., Ariyasu, H., Okuhira, H., Yamamoto, Y., Akamatsu, H., Katsuda, M., Jinnin, M., Hara, I., & Akamizu, T. (2018) · Trends in Immunotherapy · doi:10.24294/ti.v2.i2.606 · Cited by 10
Hypophysites induites par les immunothérapies anti-néoplasiques
du Payrat, J. A., Cugnet‐Anceau, C., Maillet, D., Levy, M., Raverot, G., Disse, E., & Borson‐Chazot, F. (2020) · Bulletin du Cancer · doi:10.1016/j.bulcan.2020.01.012 · Cited by 10
Iglesias, P., Soria, A., & Díez, J. J. (2015) · Medicina Clínica · doi:10.1016/j.medcli.2015.02.010 · Cited by 10
Vancieri, G., Bellia, A., & Lauro, D. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0439-3 · Cited by 9
Pituitary and adrenal disorders induced by immune checkpoint inhibitors
Albarel, F., Brue, T. C., & Castinetti, F. (2023) · Annales d Endocrinologie · doi:10.1016/j.ando.2023.03.014 · Cited by 9
Chiloiro, S., Giampietro, A., Bianchi, A., Menotti, S., Angelini, F., Tartaglione, T., Cappellini, G. A., Galitiis, F. D., Rossi, E., Schinzari, G., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030415 · Cited by 9
Zhang, X., Pan, J., Xu, R., Fu, Y., & Lv, B. (2024) · Translational Andrology and Urology · doi:10.21037/tau-24-514 · Cited by 9
Kwon, H., Roh, E., Ahn, C. H., Kim, H. K., Ku, C. R., Jung, K. Y., Lee, J. H., Kim, E. H., Suh, S., Hong, S., et al. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1627 · Cited by 8
Shah, M., Rajha, E., Dinardo, C. D., Muckey, E., Wierda, W. G., & Yeung, S. J. (2019) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2019.07.015 · Cited by 8
Chiloiro, S., Vicari, A., Mongelli, G., Costanza, F., Giampietro, A., Mattogno, P. P., Lauretti, L., Olivi, A., Marinis, L. D., Doglietto, F., et al. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-024-09898-6 · Cited by 8
Checkpoint Inhibitors in Breast Cancer - Current Status and Future Directions
Bischoff, J. (2018) · Breast Care · doi:10.1159/000486706 · Cited by 8
Immune Checkpoint Inhibitors Impact Fertility: A Review
Shabir, I., & Foster, C. (2025) · Reviews on Recent Clinical Trials · doi:10.2174/0115748871340496250130054721 · Cited by 8
Furtado, V. F., Melamud, K., Hassan, K., Rohatgi, S., & Buch, K. A. (2020) · Clinical Imaging · doi:10.1016/j.clinimag.2020.02.006 · Cited by 7
Emergency management of immune-related toxicity
Cooksley, T., Stutman, R. E., & Klotz, A. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000635 · Cited by 7
The Effect of Targeted Therapy for Genitourinary Malignancies on Sexual Function and Fertility
Holland, B. C., Shetty, Z., & Alanee, S. R. (2017) · Current Urology Reports · doi:10.1007/s11934-017-0704-9 · Cited by 7
Metadata
- Authors
- Ryder, M., Callahan, M., Postow, M. A., Wolchok, J., & Fagin, J. A.
- Affiliations
- Mayo Clinic (US)
- Weill Cornell Medicine (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Ryder, Mabel
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2014-04
- Volume
- 21
- Issue
- 2
- Pages
- 371-381
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- PMC
- PMC4573438
- OpenAlex
- W2166107256
- Cited by
- 439
- References
- 14
- Citations by year
- 2026: 12 · 2025: 20 · 2024: 23 · 2023: 21 · 2022: 32 · 2021: 44 · 2020: 49 · 2019: 55 · 2018: 53 · 2017: 56 · 2016: 44 · 2015: 25 · 2014: 5
- FWCI
- 20.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrine Related Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bristol-Myers Squibb
- GlaxoSmithKline
- National Cancer Institute (K08CA133183, P50CA172012, P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- ipilimumab, immune-related adverse events, CTLA-4 blockade, immune checkpoint inhibitors, advanced melanoma, hypophysitis, hypothyroidism, thyroiditis, adrenal dysfunction, nivolumab, anti-PD-1 therapy, hormone replacement therapy, endocrine toxicity
- MeSH terms
- Ipilimumab, Antibodies, Monoclonal, Antineoplastic Agents, Endocrine System Diseases, Humans, Melanoma, Skin Neoplasms, Testosterone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.